According to the press release [ http://www.asahi-kasei.co.jp/asahi/en/news/2018/e180802.html ], 28‐day mortality was improved 2.6% (ART‐123 group, 26.8% versus placebo group, 29.4%) in a total of 800 sepsis patients (ART‐123 group, n = 395; placebo group, n = 405) with organ dysfunction and coagulopathy (platelet count <150 × 10 9 /L and prothrombin time–international normalized ratio > 1.4), but the difference did not reach statistical significance.
← all excerpts
Oh, how hard it is to open the gate for sepsis trials: lessons from SCARLET.
1
—
—